Clinical Response
Clinical Response - Related Videos
14:37
Accessibility to Clinical Care for People who use Wheelchairs
0 Views •
2023
Source: Yetsa Tuakli-Wosornu1,2, Jaideep Talwalkar1; 1Yale School of Medicine, 2University of Pittsburgh In the United States, 25% of the general population suffers from one or another type of disability. Ambulatory disabilities, or mobility impairments, represent the most common subcategory, comprising 14% of the country's populace. Different mobility-assistive devices, ranging from canes to scooters, enable increased independence and improved quality of life for those suffering from mobility...
05:28
Clinical Imaging of Microwave Mammography
0 Views •
2025
This protocol describes the imaging procedure of a microwave imaging device for breast imaging.
08:29
Ex Vivo Treatment Response of Primary Tumors and/or Associated Metastases for Preclinical and Clinical Development of Therapeutics
0 Views •
Cited by 12 •
2014
Established cancer cell lines and xenografts have been the mainstay of cancer research for the past several decades. However, recent evidence suggests that therapeutic response is greatly influenced by the tumor cell microenvironment. Therefore, we have developed an ex vivo analysis of primary tumor specimens for drug development purposes.
10:45
Clinically Relevant Transplantable Tumor Models for Studying Metastatic Ovarian Cancer and Therapeutic Response in Mouse
0 Views •
2026
Here we present a step-by-step protocol for establishing the intraperitoneal and the intrabursal tumor models to study ovarian cancer cancer progression, metasatsis, and therapeutic response. Further, we describe how to use luciferase-based non-invasive in vivo imaging in these models to monitor tumor progression in mouse.
09:05
Determining the Phagocytic Activity of Clinical Antibody Samples
0 Views •
Cited by 33 •
2011
We present a high-throughput flow cytometric assay to determine the phagocytic activity of antigen-specific antibodies from clinical samples, utilizing fluorescent antigen-coated beads and a monocytic cell line expressing multiple Fc receptors—providing receptor usage and phagocytic activity determinations in a standardized and reproducible fashion for any antigen of interest.
FAQs
A response can shift when an intervention changes signaling pathways, immune activity, pathogen growth, or tissue function. Those biological effects may appear as improvement, no change, or worsening across symptoms, signs, laboratory findings, or overall condition. Considering several types of evidence helps distinguish a broad change in health from an isolated observation and supports meaningful treatment comparisons.
Treatment resistance is signaled when expected improvement does not occur despite an intervention, making the observed response important beyond a simple treatment judgment. Comparing response patterns across therapies can help researchers identify that resistance is present and connect an unsuccessful outcome with the biological processes a therapy was intended to alter. This information can inform later treatment decisions.
These outcomes represent different relationships between the intervention and disease state. Improvement may indicate that the targeted biological process changed in a beneficial direction, whereas no change or worsening may indicate limited effectiveness, treatment resistance, or continuing disease activity. Keeping these categories distinct allows researchers and clinicians to compare therapies and evaluate outcomes without treating every post-treatment observation as success.
They establish defined outcomes that specify what change will be evaluated, then make repeated observations of the patient’s signs, symptoms, laboratory findings, or overall condition. This structure makes response assessment more consistent over time and supports comparisons between therapies. It also helps distinguish a transient observation from a pattern relevant to effectiveness or safety.
Clinical response provides an outcome for judging whether an intervention produces beneficial, absent, or harmful change while also supporting safety evaluation. In clinical trials, response assessments help compare therapies; during drug development, they connect biological effects with observed patient outcomes. This evidence helps determine whether a treatment’s mechanism translates into a clinically meaningful result.
Patterns in signs, symptoms, laboratory findings, and overall condition can help guide care toward the intervention associated with the most useful outcome for a particular patient. At the research level, these observations connect biological mechanisms with treatment effects, including altered immune activity, signaling, pathogen growth, or tissue function. The same evidence therefore supports individualized decisions and translational research.